Today: 20 May 2026
Lattice Semiconductor (LSCC) stock price dips: what to watch before Monday’s open
26 January 2026
2 mins read

Lattice Semiconductor (LSCC) stock price dips: what to watch before Monday’s open

New York, January 25, 2026, 19:35 EST — The market has closed.

  • Shares of Lattice Semiconductor finished Friday down 1.1% at $84.33, with activity continuing into extended hours.
  • This week, risk appetite hinges on a Federal Reserve rate decision and major tech earnings reports.
  • Lattice is slated to release its quarterly earnings on Feb. 9, after the market closes, per MarketBeat estimates.

Lattice Semiconductor Corporation shares fell 1.1% on Friday, closing at $84.33. In after-hours trading, they hovered near $84.22, having swung between $82.79 and $85.79 during the regular session. Over the past year, the stock has ranged from $34.69 to $89.92. MarketBeat projects the company will release its quarterly earnings on Feb. 9 after the market closes.

Timing is crucial. Investors face a packed week with a Federal Reserve meeting and a barrage of earnings reports, while markets wrestle with how fast major AI investments will translate into profits. “It’s been a little bit of a short but steep roller-coaster ride,” said Yung‑Yu Ma, chief investment strategist at PNC Financial Services Group, referencing the sharp moves driven by geopolitics. Franklin Templeton strategist Chris Galipeau was more direct: “earnings are the driver.” Reuters

Chip stocks took a hit late last week after Intel’s shares fell 14% on Friday, weighed down by forecasts that came up short. The company blamed supply constraints as it scrambles to keep up with AI-fueled demand for data-center chips. TD Cowen analysts noted Intel’s recent rally was driven more by “the dream” than by near-term fundamentals. Intel CFO David Zinsner reassured investors that supply should improve in the second quarter. Reuters

For Lattice, the implications aren’t as straightforward but still clear. The company makes field-programmable gate arrays (FPGAs), chips that clients can reprogram post-manufacture, and its stock usually moves in line with the overall risk appetite for semiconductors and growth names.

Lattice specializes in low-power programmable chips for sectors such as communications equipment, industrial applications, and embedded computing. Its bigger competitors in programmable logic are AMD’s Xilinx division and Intel’s Altera unit, though their demand patterns can differ from quarter to quarter.

The U.S. market was closed Sunday, leaving uncertainty over whether Friday’s dip will hold once trading resumes Monday. Mega-cap tech and rate-sensitive growth stocks have been driving price action, often pulling smaller semiconductor names in their wake.

Investors will look to Lattice’s upcoming results for a clearer read. Attention will zero in on the revenue forecast, gross margin, and any signs of stabilizing orders in end markets that have been volatile — with industrial demand drawing particular scrutiny.

The setup works both ways. Should the Fed drop hints of impatience on inflation, or if big tech earnings sow doubt over AI returns, semiconductor stocks could adjust sharply. Smaller players would likely feel the brunt. A cautious outlook from Lattice on demand or inventory levels would only deepen those worries.

The Federal Open Market Committee will meet from Jan. 27 to 28, wrapping up with a policy decision set for 2:00 p.m. on Jan. 28. Chair Jerome Powell is scheduled to speak shortly after, at 2:30 p.m. that day.

LSCC traders are eyeing two key dates: the Fed’s decision on Wednesday and the company’s earnings report, due after the bell on Feb. 9.

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Zhongji Innolight (300308.SZ) stock: China’s new fund-favorite faces a Monday test after a 5.8% slide
Previous Story

Zhongji Innolight (300308.SZ) stock: China’s new fund-favorite faces a Monday test after a 5.8% slide

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Next Story

Stock Market Today 26.01.2026

Go toTop